Affordable Access

Access to the full text

Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools

Authors
  • Liu, Jiaxin1
  • Liu, Zhao2
  • Zhang, Xiaozhi3
  • Gong, Tuotuo3
  • Yao, Demao1
  • 1 First Affiliated Hospital of Xi’an Jiaotong University, Department of Geriatric Surgery, Xi’an, Shanxi, 710061, People’s Republic of China , Xi’an (China)
  • 2 First Affiliated Hospital of Xi’an Jiaotong University, Department of Oncology Surgery, Xi’an, Shanxi, 710061, People’s Republic of China , Xi’an (China)
  • 3 First Affiliated Hospital of Xi’an Jiaotong University, Department of Radiotherapy, Xi’an, Shanxi, 710061, People’s Republic of China , Xi’an (China)
Type
Published Article
Journal
BMC Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Mar 13, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12885-019-5406-x
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundGastric cancer (GC) is one of the most commonly occuring gastrointestinal tumor types, and early diagnosis and operation have a notable effect on the prognosis of patients. Although certain markers, including HER2, VEGER-2, ERCC1 and Bcl-2, have been utilized in clinical practise to screen out new patients with GC, the results of using these markers remains poor. The role of olfactomedin-like 2B (OLFML2B) in GC, as a member of the olfactomedin domain-containing proteins family, is remain unclear.MethodsIn the present study, we assessed the expression of OLFML2B, including mRNA and protein level, by using The Cancer Genome Atlas (TCGA) database and 13 pairs of clinical samples between GC and NG tissues. The correlation between expression of OLFML2B and prognosis of GC was evaculated by the Kaplan-Meier plotter and OncoLnc online tools. In addition, mechanism analysis of OLFML2B in GC was explored thought bioinformatic tools, including cBioPortal and FunRich software.ResultsIn our study, the mRNA expression of OLFML2B in GC both TCGA database and clinical samples was consistently revealed to be significantly higher compared with that in NG tissues (P < 0.0001 for TCGA database and P = 0.0034 for clinical samples), and high OLFML2B expression was found in 9 (69.23%) of 13 clinical GC by immunohistochemistry and was positively correlated with the depth of tumor invasion and clinical stage (TNM). In addition, the AUC for a ROC of 0.867 indicated a moderate diagnostic ability of OLFML2B for GC. Survival analysis from the Kaplan-Meier plotter (P = 2.6 × 10− 6) and OncoLnc (P = 0.00276) revealed that the high expression of OLFML2B was associated with a short overall survival. Futhermore, 5% (24/478) alterations of OLFML2B were identified from cBioPortal, and among them, missense mutation (14/478) was the primary type. The results from FunRich revealed that OLFML2B participated in mediating multiple biological processes including cell growth and maintenance, regulation of the cell cycle, apoptosis and cell communication through multiple signaling pathways including the M/G1 transition pathway, post-translational protein modification and DNA replication pre-initiation.ConclusionsTaken together, it could be deduced that OLFML2B may act as an oncogene in the development of GC and the overexpression of OLFML2B in GC may be used as a novel diagnostic and prognostic target for GC.

Report this publication

Statistics

Seen <100 times